The efficacy and safety of adding bevacizumab in neoadjuvant therapy for locally advanced rectal cancer patients: A systematic review and meta-analysis

摘要: Abstract Background Patients with locally advanced rectal cancer (LARC) are more likely to suffer local recurrence and distant metastases, contributing worse prognoses. Considering the provided dramatic reduction of recurrences, neoadjuvant CRT (nCRT) followed by curative resection total mesorectal excision (TME) adjuvant chemotherapy has been established as standard therapy for LARC patients. However, efficacy adding bevacizumab in therapy, especially induction therapy-containing nCRT patients remains uncertain. Materials PubMed, Embase, Web Science were searched retrieve records on application a setting The endpoints interest pCR rates suffering Grade 3/4 bevacizumab-specific adverse events, namely bleeding, wound healing complications, gastrointestinal perforation. Results 29 cohorts covering 1134 subjects included this systematic review. pooled rate bevacizumab-relevant was 21% (95% confidence interval CI), 17–25%; I2 = 61.8%), estimates complication, perforation 1% CI, 0–3%; I2 = 0%), 2% 1–5%; I2 = 4.7%), 0–5%; respectively. Conclusion addition nCRT, TNT, provides promising acceptable safety. results should be interpreted cautiously due small amount relevant data need further confirmation future studies.